FDG-PET is a good biomarker of both early response and acquired resistance in BRAF(V600) mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973

BACKGROUND: The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic melanoma in patients harboring BRAF(V600) mutations. Currently, dual BRAF and MEK inhibition are ongoing in clinical trials with the goal of overcoming the acquired resistance that has unfortunate...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Baudy, Andreas R, Dogan, Taner, Flores-Mercado, Judith E, Hoeflich, Klaus P, Su, Fei, van Bruggen, Nicholas, Williams, Simon-Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer 2012
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3405466/
https://ncbi.nlm.nih.gov/pubmed/22651703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2191-219X-2-22
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky